ASAH1 gene therapy - Genethon
Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Genethon
- Class Gene therapies
- Mechanism of Action Ceramidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Farber lipogranulomatosis; Spinal muscular atrophy
Most Recent Events
- 21 Oct 2024 Preclinical trials in Farber lipogranulomatosis in France (Parenteral), before October 2024 (Genethon pipeline, October 2024)
- 21 Oct 2024 Preclinical trials in Spinal muscular atrophy in France (Parenteral), before October 2024 (Genethon pipeline, October 2024)
- 21 Oct 2024 Genethon plans a clinical trial for Farber lipogranulomatosis and Spinal muscular atrophy (Genethon website, October 2024)